{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-004966","form_type":"8-K","ticker":"EWTX","cik":"0001710072","company_name":"Edgewise Therapeutics, Inc.","filed_at":"2024-01-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.201736+00:00","generated_at":"2026-06-06T21:21:42.941423+00:00","sec_items":["2.02","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Edgewise reports $318.4M cash, outlines 2024 milestones, terminates ATM program","bullets":["Preliminary cash, equivalents and marketable securities of $318.4M as of Dec 31, 2023; shares outstanding 70.5M.","EDG-5506: 24-month ARCH data (Becker MD) in H1 2024; 1-year CANYON data in Q4 2024.","EDG-5506: Phase 2 DUNE exercise data (Becker, LGMD, McArdle) in H1 2024; 3-month LYNX data (Duchenne) in H1 2024.","EDG-7500 Phase 1 data in healthy volunteers and oHCM patients expected Q3 2024.","Terminated ATM equity program with BofA Securities; no further sales under existing prospectus."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-004966","json":"https://secwatch.observer/filing/0001104659-24-004966.json","markdown":"https://secwatch.observer/filing/0001104659-24-004966.md","text":"https://secwatch.observer/filing/0001104659-24-004966.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1710072/000110465924004966/0001104659-24-004966-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1710072/000110465924004966/tm243583d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T21:21:42.941423+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}